Figures & data
Figure 1. Novel antibody-drug conjugates entering clinical study during 2009?2013. Data available as of November 2013.
Related Research Data
In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap
Source:
Informa UK Limited
Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.
Source:
Future Science Ltd
November 29–December 1, 2011, Geneva, Switzerland
Source:
Informa UK Limited
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
Source:
Springer Nature
A book edited by Laurent Ducry
Source:
Informa UK Limited
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Source:
Springer Science and Business Media LLC
April 30–May 1, 2012, Boston, USA
Source:
Informa UK Limited
LC–MS Challenges in Characterizing and Quantifying Monoclonal Antibodies (mAb) and Antibody-Drug Conjugates (ADC) in Biological Samples
Source:
Springer Science and Business Media LLC
November 30–December 2, 2009, Geneva, Switzerland
Source:
Informa UK Limited
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Source:
Springer Science and Business Media LLC
A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection.
Source:
Informa UK Limited
Strategies and challenges for the next generation of therapeutic antibodies
Source:
Springer Science and Business Media LLC
New linker structures applied in glycosite-specific antibody drug conjugates
Source:
Royal Society of Chemistry (RSC)
4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.
Source:
Informa UK Limited
Site-specific antibody drug conjugates for cancer therapy
Source:
Informa UK Limited
Analytical methods for physicochemical characterization of antibody drug conjugates
Source:
Informa UK Limited
Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges
Source:
American Society for Pharmacology & Experimental Therapeutics (ASPET)
March 20–21, 2012, Lyon, France
Source:
Informa UK Limited
Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection
Source:
SpringerOpen
Antibody-drug conjugates as novel anti-cancer chemotherapeutics
Source:
Portland Press Ltd.
World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
Source:
Informa UK Limited
February 29–March 1, 2012, Frankfurt, Germany
Source:
Informa UK Limited
November 27–28, 2012, Geneva, Switzerland
Source:
Informa UK Limited
Linking provided by
